Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of BRCA mutation status with the efficacy of poly (ADP-ribose) polymerase inhibitors in cancer: A systematic review and meta-analysis.

Asian journal of surgery - 1 Dec 2023

Wang Sheng, Xu Hang, Ai Jianzhong, Yang Lu

Abstract excerpt

No abstract is available from the source.

Topics

Join the communities discussing this publication.

Mutation
Ovarian Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
Ribose

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 37541880
DOI: 10.1016/j.asjsur.2023.07.118

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of BRCA mutation status with the efficacy of poly (ADP-ribose) polymerase inhibitors in cancer: A systematic review and meta-analysis.PMID 37541880Read ↗

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialSemantic proximity Read ↗

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialSemantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.Semantic proximity Read ↗

Efficacy and Safety of BRCA-targeted Therapy (Polyadenosine Diphosphate-ribose Polymerase Inhibitors) in Treatment of BRCA-mutated Breast Cancer: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: An updated systematic review and meta-analysis of randomized controlled trialsSemantic proximity Read ↗

Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: An updated systematic review and meta-analysis of randomized controlled trialsSemantic proximity Read ↗

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialSemantic proximity Read ↗

Poly(ADP-Ribose) Polymerase InhibitorsSemantic proximity Read ↗

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Cancer: Systematic Review and Network Meta-AnalysisSemantic proximity Read ↗

An update on PARP inhibitors for the treatment of cancerSemantic proximity Read ↗

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitorsSemantic proximity Read ↗

Cancer treatment according to BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.